Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nabanita Nawar, Shazreh Bukhari, Ashley Adile, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3193-3217
Closed Access | Times Cited: 21

Showing 21 citing articles:

The Role of Chronic Inflammation in Pediatric Cancer
Christine Mella, Panogiotis Tsarouhas, Maximillian Brockwell, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 154-154
Open Access | Times Cited: 3
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 667-667
Open Access | Times Cited: 33
Recent advancement of HDAC inhibitors against breast cancer
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Closed Access | Times Cited: 17
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
Al‐Hassan M. Mustafa, Oliver H. Krämer
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 35-61
Closed Access | Times Cited: 23
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
Bo Han, Mengfei Wang, Jiayi Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115613-115613
Closed Access | Times Cited: 16
Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response
Nan Sun, Kexin Yang, Wenzhong Yan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4802-4826
Closed Access | Times Cited: 14
Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity
Hyun-Mo Yang, Chang-Sik Lee, Jaeki Min, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 99, pp. 117587-117587
Closed Access | Times Cited: 5
Design, synthesis, and biological evaluation of novel artemisinin-based HDAC inhibitors with antitumor and antimalarial activities
Jin He, Youyou He, Yunan Qian, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108312-108312
Closed Access
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability
Harsimran Kaur Garcha, Olasunkanmi O. Olaoye, Abootaleb Sedighi, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor
Chen Chen, Xiaochun Ma, Yichao Wan, et al.
Bioorganic Chemistry (2025) Vol. 161, pp. 108562-108562
Closed Access
Discovery of Selective HDAC6 Inhibitors Driven by Artificial Intelligence and Molecular Dynamics Simulation Approaches
Xingang Liu, Hao Yang, Xinyu Liu, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101338-101338
Open Access
Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors
Jiangkun Yan, Kairui Yue, Xuejing Fan, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 115004-115004
Closed Access | Times Cited: 16
Design, synthesis, and biological evaluation of tetrahydroisoquinoline based hydroxamate derivatives as HDAC 6 inhibitors for cancer therapy
Yogesh Mahadu Khetmalis, Bakhya Shree, Boddupalli Venkata Siva Kumar, et al.
Journal of Molecular Structure (2023) Vol. 1278, pp. 134952-134952
Closed Access | Times Cited: 8
Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
Hyein Jo, Kyeonghee Shim, Dooil Jeoung
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9592-9592
Open Access | Times Cited: 13
Medicinal chemistry advances in targeting class I histone deacetylases
Diaaeldin I. Abdallah, Elvin D. de Araujo, Naman H. Patel, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 757-779
Open Access | Times Cited: 8
Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Anirban Mukherjee, Farzad Zamani, Takayoshi Suzuki
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 11672-11700
Open Access | Times Cited: 6
Design, Synthesis, and biological evaluation of HDAC6 inhibitors based on Cap modification strategy
Xuedong Li, Xingang Liu, Songsong Wang, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105874-105874
Closed Access | Times Cited: 9
Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy
Xingang Liu, Wenying Yan, Songsong Wang, et al.
Computers in Biology and Medicine (2023) Vol. 160, pp. 107036-107036
Closed Access | Times Cited: 5
Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies
Zsuzsanna Gaál
Biomolecules (2022) Vol. 13, Iss. 1, pp. 61-61
Open Access | Times Cited: 8
Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors
Tianyi Zhang, Xiaoyan Zhao, Xiangpei Sun, et al.
Journal of Saudi Chemical Society (2022) Vol. 26, Iss. 3, pp. 101450-101450
Open Access | Times Cited: 3
De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases
Agata Kieliszek, Daniel Mobilio, Blessing Bassey‐Archibong, et al.
Cell Reports Medicine (2024), pp. 101755-101755
Open Access
Integrated molecular modeling and dynamics approaches revealed the mechanism of selective inhibition of HDAC6/8
Yaxin Li, Sisi Liu, Ximing Xu, et al.
Journal of Biomolecular Structure and Dynamics (2023), pp. 1-14
Closed Access | Times Cited: 1
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
Harsimran Kaur Garcha, Nabanita Nawar, Helena Sorger, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1321-1321
Open Access | Times Cited: 1
Page 1

Scroll to top